DIECI, Maria Vittoria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.627
AS - Asia 2.678
EU - Europa 2.202
SA - Sud America 366
AF - Africa 74
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.959
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.555
SG - Singapore 781
CN - Cina 726
GB - Regno Unito 452
IT - Italia 419
HK - Hong Kong 374
IE - Irlanda 344
VN - Vietnam 291
BR - Brasile 288
SE - Svezia 219
DE - Germania 209
FI - Finlandia 136
KR - Corea 100
IN - India 98
RU - Federazione Russa 97
FR - Francia 90
UA - Ucraina 73
ID - Indonesia 53
TR - Turchia 53
CA - Canada 41
BD - Bangladesh 33
BG - Bulgaria 31
NL - Olanda 27
ZA - Sudafrica 22
AR - Argentina 21
IQ - Iraq 20
JP - Giappone 20
PL - Polonia 20
CO - Colombia 18
ES - Italia 18
MX - Messico 16
PK - Pakistan 15
TW - Taiwan 15
CZ - Repubblica Ceca 11
EC - Ecuador 10
EG - Egitto 10
TN - Tunisia 10
CL - Cile 9
LT - Lituania 9
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 8
IR - Iran 8
MY - Malesia 8
PH - Filippine 8
VE - Venezuela 8
AT - Austria 7
AU - Australia 7
DZ - Algeria 7
BE - Belgio 6
JO - Giordania 6
KE - Kenya 6
MA - Marocco 6
PY - Paraguay 6
TH - Thailandia 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
RO - Romania 5
AL - Albania 4
CR - Costa Rica 4
DK - Danimarca 4
IL - Israele 4
LB - Libano 4
MD - Moldavia 4
NP - Nepal 4
OM - Oman 4
PT - Portogallo 4
BH - Bahrain 3
BO - Bolivia 3
EU - Europa 3
GR - Grecia 3
JM - Giamaica 3
KZ - Kazakistan 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
CH - Svizzera 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MM - Myanmar 2
NG - Nigeria 2
PE - Perù 2
PS - Palestinian Territory 2
SN - Senegal 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BB - Barbados 1
BJ - Benin 1
BN - Brunei Darussalam 1
CY - Cipro 1
ET - Etiopia 1
GA - Gabon 1
GY - Guiana 1
HU - Ungheria 1
KH - Cambogia 1
LV - Lettonia 1
ME - Montenegro 1
MT - Malta 1
Totale 9.951
Salva come PNG Salva come JPEG
Città #
Singapore 524
Santa Clara 502
Ashburn 468
Fairfield 391
Hong Kong 368
Dublin 344
Woodbridge 235
Southend 229
Chandler 219
San Jose 214
Hefei 207
Houston 179
Seattle 173
Ann Arbor 135
Cambridge 134
Beijing 133
Dearborn 132
Wilmington 127
Jacksonville 115
Nyköping 113
London 111
The Dalles 100
Los Angeles 99
Council Bluffs 93
Helsinki 92
Ho Chi Minh City 90
Chicago 89
Seoul 84
Hanoi 80
New York 54
Dallas 48
Modena 48
Munich 46
Jakarta 45
Shanghai 44
Lauterbourg 43
Moscow 43
San Diego 42
Princeton 34
Milan 32
São Paulo 32
Sofia 31
Eugene 25
Rome 23
Tampa 23
Izmir 22
Salt Lake City 21
Buffalo 20
Elk Grove Village 20
Frankfurt am Main 20
Orem 19
Bologna 18
Falls Church 18
Mumbai 18
Naples 16
Turin 16
Des Moines 15
Dong Ket 15
Guangzhou 15
Norwalk 15
Redwood City 15
Columbus 14
Kent 14
Lappeenranta 14
Phoenix 14
Tokyo 14
Boston 13
Chennai 13
Nuremberg 13
Ottawa 13
Turku 13
Amsterdam 12
Bremen 12
Redondo Beach 12
Warsaw 12
Taipei 11
Da Nang 10
Florence 10
Fremont 10
Atlanta 9
Denver 9
Haiphong 9
Johannesburg 9
Kunming 9
Padova 9
Sterling 9
Changsha 8
Dhaka 8
Lancaster 8
Montreal 8
Nanjing 8
Rio de Janeiro 8
Boardman 7
Brooklyn 7
Catania 7
Curitiba 7
Toronto 7
Wuhan 7
Biên Hòa 6
Cape Town 6
Totale 7.065
Salva come PNG Salva come JPEG
Nome #
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 425
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 416
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 377
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 364
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 339
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 334
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 327
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 304
Immune characterization of breast cancer metastases: prognostic implications. 302
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 291
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 288
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 286
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 281
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 280
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 254
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 253
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 242
Timing for starting second-line therapy in recurrent ovarian cancer 239
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 234
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 220
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 217
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 214
Tumori ginecologici 213
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 198
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY. 192
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 190
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 187
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 187
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 182
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 180
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 179
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 171
MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT 163
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 162
Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials 160
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts 155
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8) 145
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â € "Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 132
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC). 123
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 116
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study 100
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers 97
Pregnancy after Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study 89
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 88
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients. 69
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial. 37
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial. 28
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial. 15
Totale 10.045
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.536
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.536
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021268 0 0 0 0 0 0 0 0 0 120 101 47
2021/2022630 29 73 77 19 25 35 32 33 66 60 120 61
2022/2023961 74 97 43 53 63 97 16 60 399 7 25 27
2023/2024572 24 24 30 27 77 39 69 118 25 23 39 77
2024/20251.888 54 27 30 139 360 313 138 103 182 107 188 247
2025/20263.576 271 142 305 425 630 248 534 219 374 428 0 0
Totale 10.045